The strength of our balance sheet and our strategic collaborations with major biotechnology and pharmaceutical companies provide us with the resources needed to fuel our R&D activities.

More »

Led by a product for multiple sclerosis entering phase 3, we have a pipeline of five products in the clinic.

More »

We are committed to keeping our investors, partners and clinical investigators apprised of our vision and business operations in a timely manner.  Learn more about our recent scientific presentations and investor and other conferences.

More »